Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations

Published on May 1, 2020in Blood Reviews6.125
· DOI :10.1016/J.BLRE.2019.100647
F. Zaja (DSM), Monica Carpenedo9
Estimated H-index: 9
+ 8 AuthorsPotito Rosario Scalzulli17
Estimated H-index: 17
(Casa Sollievo della Sofferenza)
Abstract Thrombopoietin receptor agonists (TPO-RAs) are currently indicated for continuous treatment of chronic primary immune thrombocytopenia (ITP). However, there is growing evidence that TPO-RAs can also trigger sustained response in 10–30% of cases after treatment tapering and discontinuation. Therefore, at least for selected responding patients, it might be rational to plan TPO-RA interruption to exploit off-treatment response. Intriguingly, complete or partial responses with TPO-RAs are frequently observed when treatments are initiated early, suggesting that unknown immune-related mechanisms may be involved in this phenomenon. The sustained responses observed after interruption of TPO-RAs may be interpreted as a recovery of immunological tolerance; thus, the re-establishment of immunological equilibrium might be primarily responsible for the observed off-treatment effect. Importantly, these findings may indicate that anticipated TPO-RA usage can lead to improved responses, and that optimized tapering and interruption in selected patients can furthermore improve prognoses. On the base of this rationale, a series of real-life considerations have been generated by a panel of Experts to elucidate possible novel criteria and modalities to identify subgroups of patients who can benefit from tapering and/or discontinuation of TPO-RAs. Towards this aim, the results of a survey of ITP experts are herein reported, reflecting a snapshot of current real-life experience on early discontinuation of TPO-RA-based therapy. The present manuscript also highlights the importance of future translational studies on novel prognostic and predictive biomarkers that can stratify patients and facilitate the clinical choice for second-line treatment of ITP.
  • References (55)
  • Citations (0)
📖 Papers frequently viewed together
12 Citations
14 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
The purpose of this document, a result of the harmonisation and revision of Guidelines published separately by the SIMFER, SIOMMMS/SIR, and SIOT associations, is to provide practical indications based on specific levels of evidence and various grades of recommendations, drawn from available literature, for the management of osteoporosis and for the diagnosis, prevention, and treatment of fragility fractures. These indications were discussed and formally approved by the delegates of the Italian S...
12 CitationsSource
#1Jan-Paul Bohn (Innsbruck Medical University)H-Index: 3
#2Michael Steurer (Innsbruck Medical University)H-Index: 20
Immune thrombocytopenia (ITP) is an acquired autoimmune phenomenon resulting in low platelet count and increased bleeding risk. Goals of upfront management include prompt control of severe bleeding—which is rare—as well as induction and maintenance of a hemostatic platelet count. Thus, optimal management of ITP patients is often challenging and requires a highly individualized approach. Many patients may not suffer significant bleeding despite severe thrombocytopenia and the risk of toxicity ass...
2 CitationsSource
2 CitationsSource
#1Aldo Bonaventura (UniGe: University of Genoa)H-Index: 17
#2Fabrizio Montecucco (UniGe: University of Genoa)H-Index: 38
Abstract Corticosteroids are widely diffused drugs. An important side effect is the impairment of glycemic control both in patients with known diabetes and in normoglycemic ones potentially leading to steroid-induced diabetes mellitus (SIDM). In this review based on papers released on PubMed, MEDLINE, and EMBASE from January 2015 to October 2017, we summarized and discussed main updates about the definition, the diagnosis, and the pathophysiology of steroid-induced hyperglycemia (SIH), with a lo...
7 CitationsSource
#1Raymond S. M. Wong (CUHK: The Chinese University of Hong Kong)H-Index: 26
#2Mansoor N. Saleh (UAB: University of Alabama at Birmingham)H-Index: 49
Last. James B. Bussel (Cornell University)H-Index: 75
view all 7 authors...
In phase 2/3 trials, eltrombopag treatment of 6 months or less in patients with chronic/persistent immune thrombocytopenia (ITP) increased platelet counts and reduced bleeding. The open-label EXTEND study evaluated long-term safety and efficacy of eltrombopag in adults with ITP who had completed a previous eltrombopag study. For the 302 patients enrolled, median duration of eltrombopag treatment was 2.37 years (2 days-8.76 years). Median platelet counts increased to 50 × 10 9 /L or more by week ...
40 CitationsSource
#1Raymond S. M. Wong (CUHK: The Chinese University of Hong Kong)H-Index: 10
#2Russell K. Brynes (SC: University of Southern California)H-Index: 41
Last. Tahir ShamsiH-Index: 12
view all 9 authors...
Background: ITP, characterized by isolated platelet reduction, is classified as persistent within 3- et al. Acta Haematol 2017;137:66-72) was performed. Aims: To evaluate the effects of EPAG on platelet counts, and long-term safety, during 2 yrs9 treatment, in persistent or cITP pts. Methods : Adults ≥18 yrs old diagnosed with persistent ITP (3- Results: At BL, 37/162 (23%; mean ± SD age 44 ± 16 yrs; 57% female) and 124 (77%; mean ± SD age 43 ± 16 yrs; 66% female) pts had persistent or cITP, res...
> > > In the last decade, after the initial reports of thrombotic events in patients exposed to the thrombopoietin-receptor agonists (TPO-RA) romiplostim and eltrombopag, large epidemiological investigations have been conducted to establish if increased thrombotic risk could be a hitherto
5 CitationsSource
Since its discovery, the thrombopoietin (TPO) pathway has been an important pharmaceutical target for the treatment of thrombocytopenia. The first generation of TPO mimetics included peptide agents sharing homology with endogenous TPO, but these introduced a risk of antibody formation to endogenous TPO and were not successful. However, second-generation TPO mimetics or TPO receptor agonists (RAs) are currently being used to treat thrombocytopenia associated with a number of conditions, such as i...
12 CitationsSource
#1Lenore M. Buckley (Yale University)H-Index: 4
#2Gordon H. Guyatt (McMaster University)H-Index: 201
Last. Timothy E. McAlindon (Tufts University)H-Index: 57
view all 21 authors...
Objective To develop recommendations for prevention and treatment of glucocorticoid-induced osteoporosis (GIOP). Methods We conducted a systematic review to synthesize the evidence for the benefits and harms of GIOP prevention and treatment options. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of evidence. We used a group consensus process to determine the final recommendations and grade their strength. The guideline addresses ini...
106 CitationsSource
#1Lenore M. Buckley (Yale University)H-Index: 4
#2Gordon H. Guyatt (McMaster University)H-Index: 201
Last. Timothy E. McAlindon (Tufts Medical Center)H-Index: 57
view all 21 authors...
53 CitationsSource
Cited By0
Thrombopoietin receptor agonists (TPO-RAs) are used for treatment of chronic immune thrombocytopenia (ITP). Several studies have shown that TPO-RAs induce remission and sustained response, despite long-term discontinuation of therapy. Furthermore, TPO-RAs are effective in patients with newly diagnosed ITP. Here, we retrospectively assessed all patients with ITP who received TPO-RAs in our hospital, focusing on newly diagnosed, non-splenectomized patients who had discontinued TPO-RAs due to susta...